Meeder Asset Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,036
| Closed | -$46K | – | 1022 |
|
|
2026
Q1 | $46K | Buy |
+2,036
| New | +$45.2K | ﹤0.01% | 460 |
|
|
2025
Q3 | – | Sell |
-3,227
| Closed | -$77.1K | – | 910 |
|
|
2025
Q2 | $77.1K | Buy |
+3,227
| New | +$81.3K | ﹤0.01% | 324 |
|
|
2022
Q4 | – | Sell |
-19
| Closed | -$1K | – | 1641 |
|
|
2022
Q3 | $1K | Buy |
19
+6
| +46% | +$334 | ﹤0.01% | 1992 |
|
|
2022
Q2 | $1K | Buy |
13
+4
| +44% | +$262 | ﹤0.01% | 2049 |
|
|
2022
Q1 | $1K | Buy |
+9
| New | +$600 | ﹤0.01% | 2227 |
|
|
2021
Q4 | – | Sell |
-1
| Closed | – | – | 2003 |
|
|
2021
Q3 | $0 | Buy |
+1
| New | +$58 | ﹤0.01% | 2596 |
|
|
2020
Q2 | – | Sell |
-3,998
| Closed | -$135K | – | 2348 |
|
|
2020
Q1 | $135K | Sell |
3,998
-6,249
| -61% | -$260K | 0.01% | 650 |
|
|
2019
Q4 | $464K | Buy |
10,247
+9,746
| +1,945% | +$414K | 0.03% | 418 |
|
|
2019
Q3 | $18K | Sell |
501
-5,658
| -92% | -$226K | ﹤0.01% | 1351 |
|
|
2019
Q2 | $268K | Sell |
6,159
-64
| -1% | -$2.72K | 0.02% | 516 |
|
|
2019
Q1 | $237K | Buy |
6,223
+1,620
| +35% | +$63.2K | 0.02% | 507 |
|
|
2018
Q4 | $198K | Buy |
4,603
+4,483
| +3,736% | +$209K | 0.02% | 501 |
|
|
2018
Q3 | $6K | Buy |
120
+22
| +22% | +$951 | ﹤0.01% | 1299 |
|
|
2018
Q2 | $3.14K | Hold |
98
| – | – | ﹤0.01% | 1346 |
|
|
2018
Q1 | $3K | Buy |
+98
| New | +$3.49K | ﹤0.01% | 1330 |
|
|
2017
Q3 | – | Sell |
-59
| Closed | -$3K | – | 1728 |
|
|
2017
Q2 | $3K | Sell |
59
-233
| -80% | -$10.8K | ﹤0.01% | 1332 |
|
|
2017
Q1 | $13K | Sell |
292
-298
| -51% | -$12.9K | ﹤0.01% | 797 |
|
|
2016
Q4 | $19K | Buy |
+590
| New | +$19.7K | ﹤0.01% | 666 |
|
|
2015
Q4 | – | Sell |
-500
| Closed | -$21K | – | 845 |
|
|
2015
Q3 | $21K | Hold |
500
| – | – | ﹤0.01% | 647 |
|
|
2015
Q2 | $35K | Hold |
500
| – | – | ﹤0.01% | 422 |
|
|
2015
Q1 | $44K | Hold |
500
| – | – | ﹤0.01% | 459 |
|
|
2014
Q4 | $44K | Hold |
500
| – | – | 0.01% | 408 |
|
|
2014
Q3 | $48K | Sell |
500
-200
| -29% | -$19.5K | 0.01% | 315 |
|
|
2014
Q2 | $64K | Hold |
700
| – | – | 0.01% | 281 |
|
|
2014
Q1 | $49K | Hold |
700
| – | – | 0.01% | 286 |
|
|
2013
Q4 | $40K | Hold |
700
| – | – | 0.01% | 303 |
|
|
2013
Q3 | $34K | Hold |
700
| – | – | 0.01% | 286 |
|
|
2013
Q2 | $20K | Buy |
+700
| New | +$20.3K | ﹤0.01% | 304 |
|
Other funds holding PCRX
DPCM
Meeder Asset Management's PCRX Position: Q2 2026 in Review
Meeder Asset Management sold out of Pacira BioSciences (PCRX) in Q2 2026, closing a stake of 2,036 shares — an estimated $46K sold.
Meeder Asset Management first reported a position in PCRX in Q2 2013 and held it in 28 quarters. The position peaked at $464K in Q4 2019. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.
- Meeder Asset Management reported no remaining Pacira BioSciences position as of Q2 2026 after selling out during the quarter.
- Meeder Asset Management sold 2,036 Pacira BioSciences shares in Q2 2026, an estimated $46K.
- Meeder Asset Management first reported a position in Pacira BioSciences in Q2 2013 and held it in 28 quarters.
- Meeder Asset Management's Pacira BioSciences position peaked at $464K in Q4 2019.
- 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.
Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.